查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞表面标记物检测市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)
市场调查报告书
商品编码
1190258

细胞表面标记物检测市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Cell Surface Markers Detection Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，细胞表面标誌物检测市场的复合年增长率预计为 8.2%。

预计 COVID-19 大流行将对市场产生重大影响。 细胞表面标记是指附着在细胞膜上的碳水化合物和蛋白质，使细胞表面标记在细胞间信号传导中发挥重要作用。 许多研究都是利用 COVID-19 抗体与细胞表面标记物之间的相互作用进行的。 例如，2021 年 2 月，发表在 Frontiers in Immunology 上的一篇题为“COVID-19 Impairs Immune Response to Candida Albicans”的研究论文比较了 COVID-19 患者与健康对照者单核细胞上的细胞表面标誌物表达，正在研究中。 他们发现 COVID-19 患者的继发性真菌感染率增加。 许多 COVID-19 患者的免疫系统较弱，这增加了继发性真菌感染的发生率。 因此，使用细胞表面标记进行真菌感染研究有望促进市场增长。 这些努力导致了更好地了解疾病和找到治疗方法的创新方法。 全球越来越多的此类研究项目正在使用细胞表面标记来研究 COVID-19 的影响。 因此，此类新兴市场的发展有望推动市场增长。

推动市场增长的关键因素包括对精准医疗的需求不断增长、诊断的使用不断增加以及与提高吞吐量和自动化相关的技术进步。 例如，已经鑑定出 200 多种在肺癌中过度表达的细胞表面标誌物，例如细胞角蛋白片段 21-1 和 EGFR 基因突变。 诊断方法用于通过这些标记检测血液中肿瘤细胞的存在。 全球癌症患者数量的增加预计将对生物标誌物的需求产生积极影响，从而推动细胞表面标誌物检测市场的增长。 例如，根据 Globocan 2020 报告，2020 年乳腺癌患者总数为 2,261,419 人，其次是肺癌患者（2,206,771 人）和前列腺癌患者（1,414,259 人）。 因此，全球肺部疾病患病率的增加支持了预测期内的市场增长。

精准医学，也称为个性化医学，是根据每个患者的特点量身定制的药物。 这些药物指导医疗保健决策，为个体患者提供最有效的治疗方法。 由于细胞表面标记充当有助于识别和分类细胞的字母组合，因此在癌细胞表面表达的蛋白质充当特定肿瘤类型的标记。 这种分子鑑定正在推动市场的增长，因为它有助于诊断疾病、寻找疾病的直接治疗方法和药物发现。 许多公司都参与了市场准备，这有望促进市场的增长。 例如，Becton, Dickinson and Company 为研究机构生产 BD Lyoplate 人细胞表面标誌物筛选组合。 它可用于筛选原代细胞、组织和细胞系。 兼容流式细胞术和生物成像技术平台。 面向如此广泛应用的创新产品有望推动市场增长。

细胞表面标记物检测的市场趋势

流式细胞术领域有望增长最快

流式细胞术技术用于识别群体中的不同细胞类型。 在流式细胞术中，单个细胞被高度聚焦的激光照射。 样品中加入了对感兴趣的细胞表面标记物具有特异性的抗体，并允许与细胞相互作用。 该抗体附着在具有发射不同波长光的特性的荧光染料上。 然后它们激发荧光染料，照亮细胞群并捕获发射的光。 然后可以使用由一系列直方图和点图组成的门控策略将细胞分为基于标记的亚群。 细胞表面表达的细胞表面标誌物可以用荧光标记的抗体标记，并通过流式细胞仪分析以确定细胞亚型和功能。

根据2021年9月发表在Star Protocol上的“Flow cytometry detection of surface and intracellular antigens in pancreas from a single mouse embryote”研究，采用流式细胞术检测了单个胚胎胰腺中的细胞表面蛋白，并进行了定量分析。执行。 同时检测报告蛋白、细胞表面蛋白和细胞内蛋白，从而在减少所需动物数量的同时发现生物变异体。 这样，由于上述优点，流式细胞术的细胞检测有望扩大该领域的市场。

流式细胞术的作用也已扩展到使用细胞表面标记研究免疫系统疾病，包括原发性免疫缺陷。 例如，通过流式细胞术进行的细胞表面染色通常用于研究淋巴细胞克隆性。 T 细胞克隆性研究对于评估与受限 T 细胞相关的原发性免疫缺陷病特别有用。 根据2019年发表在JACI Online上的题为“Flow cytometry: Surface Markers and beyond”的研究，流式细胞术作为一种临床检测方法的应用是识别细胞表面标誌物，它已经从鑑定到细胞内蛋白质的表征，提供多种不同的方法来评估免疫功能以及表征和诊断免疫疾病。 流式细胞术广泛用于癌症诊断。 人类发展指数 (HDI) 高的国家在医疗保健方面投入巨资。 因此，这些国家正在进行更多的癌症诊断测试□□并发现更多的癌症病例（国际癌症研究机构，2020 年），这有望推动市场增长。

但是，预计主要市场参与者增加产品发布将推动这一细分市场的发展。 例如，2020 年 6 月，Sysmex America Inc. 宣布推出 XF-1600 流式细胞仪，为实验室的广泛应用提供更高的灵活性和效率。

因此，上述所有因素预计将在预测期内推动该细分市场的增长。

北美主导市场，预计在预测期内将保持其份额

北美是最大的细胞表面标记市场。 疾病诊断应用的快速扩展、成熟研究机构的存在以及生物技术行业是推动市场规模的主要因素。 美国目前在北美细胞表面标誌物检测市场占据主导地位，预计未来几年仍将如此。 高医疗保健支出、高技术采用率以及对准确及时诊断的日益关注正在推动美国市场的增长。

美国有许多公司从事该行业，预计该国的需求在预测期内将保持强劲。 总部位于美国的公司包括 Nexcelom Bioscience LLC、Cofactor Genomics Inc.、Abbott Laboratories 和 Beckman Coulter Inc.。 这些公司增加产品发布预计将推动市场增长。 例如，2020年11月，美国研究和临床诊断公司Bio-Rad Laboratories Inc.推出了三款专为流式细胞仪开发的StarBright Dyes。 这些染料包括 StarBright Blue 700、StarBright Violet 440 和 StarBright Violet 610，它们是与 Bio-Rad 流动抗体结合的荧光纳米颗粒，可提供最大亮度和改进的分辨率。 可用于市场检测中表面蛋白的检测。 此外，2020 年 10 月，Becton, Dickinson & Company 宣布其集成了 BD FACSDuet 样品製备系统的 BD FACSLyric 流式细胞仪已获得美国 FDA 的 510(k) 许可。 主要参与者的此类举措可能会促进市场的增长。

因此，上述所有因素都有望在预测期内推动市场增长。

细胞表面标誌物检测市场竞争分析

细胞表面标誌物检测市场由许多全球参与者组成，尤其是在仪器方面，例如 Becton、Dickinson and Company、Nihon Kohden Corporation、Luminex Corporation、Sysmex Corporation 和 Thermo Fisher Scientific Inc。 然而，一些生物企业活跃于试剂和耗材等利基领域。 目前正在进行进一步整合，参与者主要专注于获取新技术。 此外，一些主要的市场进入者正专注于收购产品线和品牌。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 扩大在诊断领域的应用
    • 吞吐量和自动化方面的技术进步
    • 对精准医学的需求不断增长
  • 市场製约因素
    • 设备成本高
    • 技术复杂性
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（市场规模 - 百万美元）

  • 产品名称
    • 流式细胞术
    • 血液分析仪
    • 细胞成像系统
    • 试剂和试剂盒
    • 其他产品
  • 用法
    • 疾病诊断与鑑定
    • 研究和药物发现
    • 其他用途
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Danaher Corporation（Beckman Coulter Inc.）
    • Becton, Dickinson and Company
    • Bio Rad Laboratories Inc.
    • F. Hoffmann-La Roche Ltd
    • Diasorin SpA（Luminex Corporation）
    • Nihon Kohden Corporation
    • Qiagen NV
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • Grifols SA
    • Nexcelom Bioscience LLC
    • IVD Medical Holding Limited（Immucor Inc.）
    • Agilent Technologies Inc.
    • Sysmex Corporation

第7章 市场机会与今后动向

简介目录
Product Code: 66039

The cell surface markers detection market is estimated to register a CAGR of 8.2% during the forecast period, 2022-2027.

The COVID-19 pandemic is expected to have a significant impact on the market. Cell surface markers refer to carbohydrates and proteins that are attached to the cell membrane, allowing cell surface markers to play a crucial role in intercellular signaling. Many research projects are being carried out that involve the interaction of COVID-19 antibodies with cell surface markers. For example, in February 2021, a research article titled 'COVID-19 Impairs Immune Response to Candida Albicans', published in Frontiers in Immunology, studied and compared the cell surface marker expression on the monocytes of COVID-19 patients with healthy controls. The study found an increased rate of fungal co-infections in COVID-19 patients. The rate of secondary fungal infections increases in many COVID-19 patients due to their decreased immunity. Thus, the use of cell surface markers to study fungal infection is expected to boost the market's growth. Such initiatives help drive a better understanding of the disease, leading to innovative ways to find a cure. More such research projects are being conducted worldwide, where cell surface markers are used to study the effect of COVID-19. Thus, such developments are expected to boost the market's growth.

The major factors driving the market's growth include the increasing demand for precision medicine, increased use of diagnostics, and technological advances related to increased throughput and automation. For example, over 200 cell-surface markers have been identified as being overexpressed in lung cancers, including cytokeratin fragment 21-1 and EGFR gene mutation. Diagnostic procedures are used to detect the presence of tumor cells in the blood through these markers. An increase in the number of cancer cases worldwide is expected to positively impact the demand for biomarkers, thus boosting the growth of the cell surface markers detection market. For instance, according to the Globocan 2020 report, the total number of breast cancer cases in 2020 was 2,261,419, followed by lung cancer cases (2,206,771) and prostate cancer cases (1,414,259). Thus, growing prevalence of the lung across across globe supports the market growth over the forecast period.

Precision medicine also known as personalized medicine, is the tailored medication given according to the individual patient's characteristics. These medicines guides healthcare decisions towards a most effective treatment for an individual patient. Since cell surface markers serve as monograms to help identify and classify cells, the proteins expressed on the surface of cancerous cells serve as markers of specific tumor types. This molecule identification helps in disease diagnoses, finding direct treatment for the disease, and drug discovery, thus boosting the market's growth. Many companies are involved in market preparation, which is likely to boost the market's growth. For instance, Becton, Dickinson and Company manufactures the BD Lyoplate Human Cell Surface Marker Screening Panel for research laboratories. It can be used for screening primary cells or tissues and cell lines. It is compatible with flow cytometry and bioimaging technology platforms. Such innovative products with a wide variety of applications are expected to boost the market's growth.

Cell Surface Markers Detection Market Trends

Flow Cytometry Segment is Expected to Grow at the Fastest Rate

The technique of flow cytometry is used to identify different cell types in a population. Single cells are subjected to an intensely focused laser during the procedure. In a sample, interest-related cell surface markers-specific antibodies are added and given time to interact with the cells. Fluorochromes, which have the property of emitting light at various wavelengths, are coupled with these antibodies. The fluorochromes are then excited and the light emitted is captured as the cell population is then passed through a laser. The cells can then be divided into subpopulations based on the markers by using a gating strategy, which consists of a series of histograms and dot plots. Cell surface markers expressed on the cell surface can define cell subtypes and function when they are labeled with fluorescent-labeled antibodies and analyzed by flow cytometry.

According to the study titled "Flow cytometry detection of surface and intracellular antigens in pancreas from a single mouse embryo" published in the Star Protocol in September 2021, Flow cytometry was used to perform a quantitative cell surface protein analysis on a single embryonic pancreas. Detection of reporter, cell surface, and intracellular proteins all at the same time. Allows for the discovery of biological variation while also reducing the number of animals required. Thus, due to above mentned benefits of the flow cytometry in detection of cell, surgace markets anticipated to boost the segment growth.

The role of flow cytometry has broadened to include the study of immune system disorders, including primary immunodeficiency disorders, by using cell surface markers. For instance, cell-surface staining using flow cytometry is often used to investigate lymphocyte clonality. T-cell clonality studies are particularly useful to evaluate primary immunodeficiency disorders associated with a restricted T-cell. According to a study titled 'Flow cytometry: Surface markers and beyond' published in JACI Online in 2019, the application of flow cytometry as a clinical laboratory method evolved from the identification of cell-surface markers to characterizing intracellular proteins and providing multiple different approaches to assess immune function and characterizing and diagnosing immunologic disorders. Flow cytometry is used extensively in diagnosing cancer. Countries with a high Human Development Index (HDI) invest more in healthcare. Thus, more cancer diagnostic tests are conducted, and more cancer cases are detected in these countries (International Agency for Research on Cancer, 2020), which will likely boost the market's growth.

However, increasing product launches by the key market players anticipated to boost the segment. For Instance, In June 2020, Sysmex America Inc. announced the launch of its XF-1600 flow cytometer that provides laboratories with improved flexibility and efficiency for a wide range of applications.

Thus, all above mentioned factors expected to drive the segment growth over the forecast period.

North America Dominates the Market and is Expected to Retain its Market Share During the Forecast Period

The North American region is the largest market for cell surface markers. Rapidly growing applications in disease diagnostics, the presence of well-established research institutions, and the biotech industry are the primary factors behind the large market size. United States currently dominates the cell surface marker detection market in North America, and it is expected to continue its stronghold for a few more years. High healthcare expenditure, a high technological adaptation rate, and an increasing focus on precise and timely diagnostics are driving the market growth in United States.

United States has many companies operating in this sector, owing to which demand from the country is expected to be robust during the forecast period. Some US-based companies in the market include Nexcelom Bioscience LLC, Cofactor Genomics Inc., Abbott Laboratories, and Beckman Coulter Inc. The increased product launches by these players are expected to boost the market growth. For example, in November 2020, Bio-Rad Laboratories Inc., a US-based research and clinical diagnostic company, launched three StarBright Dyes specifically developed for flow cytometry. The dyes include StarBright Blue 700, StarBright Violet 440, and StarBright Violet 610, and they are fluorescent nanoparticles conjugated to Bio-Rad's flow antibodies, providing maximal brightness and improved resolution. They can be used for detecting surface proteins in market detection. Additionally, in October 2020, Becton, Dickinson and Company announced that it received 510(k) clearance from the US FDA for BD FACSLyric Flow Cytometer with the integrated BD FACSDuet Sample Preparation System.Such initiatives by major players are likely to boost the market's growth.

Thus, all aforementioned factors expected to boost the market growth over the forecast period.

Cell Surface Markers Detection Market Competitive Analysis

The cell surface markers detection market consists of many global players, especially on the instrument front, including Becton, Dickinson and Company, Nihon Kohden Corporation, Luminex Corporation, Sysmex Corporation, and Thermo Fisher Scientific Inc. However, several biotech start-ups are active in the reagent, consumables, and other niche fields. There is an ongoing trend of further consolidation, with players mainly focusing on acquiring new technology. Some key market participants are also focusing on acquiring product lines and brands.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Use in Diagnostics
    • 4.2.2 Technological Advances Related to Increased Throughput and Automation
    • 4.2.3 Increasing Demand for Precision Medicine
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Complexity of Techniques
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 Product
    • 5.1.1 Flow Cytometry
    • 5.1.2 Hematology Analyzers
    • 5.1.3 Cell Imaging Systems
    • 5.1.4 Reagents and Kits
    • 5.1.5 Other Products
  • 5.2 Application
    • 5.2.1 Disease Diagnosis and Identification
    • 5.2.2 Research and Drug Discovery
    • 5.2.3 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Bio Rad Laboratories Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Diasorin SpA (Luminex Corporation)
    • 6.1.7 Nihon Kohden Corporation
    • 6.1.8 Qiagen NV
    • 6.1.9 Siemens Healthineers
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Grifols SA
    • 6.1.12 Nexcelom Bioscience LLC
    • 6.1.13 IVD Medical Holding Limited (Immucor Inc.)
    • 6.1.14 Agilent Technologies Inc.
    • 6.1.15 Sysmex Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS